Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Lupin Limited    LUPIN   INE326A01037

SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Lupin Limited : Lupin Looking for Acquisitions of up to $500 Million in US

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/01/2012 | 12:39pm CET

--Looking for buys in skin care, eye care, respiratory and women's health products

--Trying to expand pipeline of low-competition generic drugs for US market

(Adds executive's comments in 7th, 9th, 12th and 13th paragraphs, background and context elsewhere)

By Rumman Ahmed

BANGALORE--Lupin Ltd. (500257.BY) is looking to aggressively grow its business in the U.S. and is scouting for acquisitions of pharmaceutical brands and manufacturers, and seeking regulatory approval to sell a wider range of niche generic drugs.

The U.S. is Lupin's primary growth market, accounting for 35% of its sales.

The India drug maker is benefiting from a wave of patent expiries for popular drugs in the U.S. But to keep the business momentum going once the "patent cliff" wave wanes, Lupin is looking to acquire branded products that are much bigger that its previous purchases.

"We've looked at small-sized acquisition opportunities as well as opportunities in the $400 million-$500 million price range," group president Vineeta Gupta recently told Dow Jones Newswires.

Unlike most of its local rivals, Lupin's business model for the world's largest pharmaceuticals market is not limited to selling drug copies: It also sells branded products like antibiotic Suprax and anti-cholesterol drug Antara. While the branded products contribute about 25% of Lupin's U.S. revenue, they make up a larger share of its profit.

Lupin is looking for acquisitions to revive the momentum in the branded-products business at a time when existing brands are likely to come up against generic competition.

The company would prefer acquisitions in the areas of skin care, eye care, respiratory and women's health products, which are more in line with the company's commercial infrastructure in the U.S., Ms. Gupta said.

The company's 160-person sales force in the U.S. is focused on selling branded products to the pediatric and primary-care market segments.

Ms. Gupta, who also heads Lupin's U.S. unit, said Lupin had mulled acquiring eye-care company ISTA Pharmaceuticals Inc., but found it wasn't a "good fit."

Eye-products maker Bausch & Lomb Inc. purchased ISTA for about $500 million in cash in a deal that closed in June.

Lupin's previous acquisitions in the U.S. were much smaller in comparison. In 2009 it paid $38.61 million to bankrupt Oscient Pharmaceuticals Corp. for Antara, and acquired AllerNaze nasal spray from U.S.-based Collegium Pharmaceutical Inc. for an undisclosed amount.

As for its generic drugs business, Lupin is trying to move its pipeline to products that are exclusive and face less competition, Ms. Gupta said.

Lupin has already applied to sell generic versions of about 31 oral contraceptive products and some eye treatments. It has also filed the first generic drug application with the U.S. regulator for a skin care product in the January-March period, she added.

Benefits from selling these drugs, which have relatively high entry barriers and offer higher-than-average margins, are expected to kick in from the fiscal year starting next April.

Write to Rumman Ahmed at rumman.ahmed@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LUPIN LIMITED
12:34p LUPIN : receives tentative approval for Generic Zorvolex Capsules
12/05 LUPIN : bags USFDA approval for Generic Norco Tablets
12/02 LUPIN : and Eli Lilly expand partnership in India
12/02 LUPIN : Partners eli lilly to sell diabetes drug 'eglucent'
12/01 LUPIN : and Eli Lilly expand partnership in India; launches Eglucent, a rapid-ac..
11/30 LUPIN : receives FDA nod for generic Nuvigil Tablets; Stock up 1%
11/29 LUPIN : Receives FDA Approval for Generic Nuvigil® Tablets
11/24 LUPIN : Gets us nod for hiv drug
11/23 LUPIN : receives tentative approval for Generic Epzicom tablets
11/17 LUPIN : shines after FDA approval
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ( INR)
Sales 2017 173 687 M
EBIT 2017 38 329 M
Net income 2017 28 804 M
Debt 2017 46 665 M
Yield 2017 0,56%
P/E ratio 2017 23,72
P/E ratio 2018 20,69
EV / Sales 2017 4,26x
EV / Sales 2018 3,62x
Capitalization 693 186 M
More Financials
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 45
Average target price 1 721  INR
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Nilesh Deshbandhu Gupta Managing Director & Executive Director
Vinita Gupta Sharma Chief Executive Officer & Executive Director
Desh Bandhu Gupta Chairman
Ramesh Swaminathan Chief Financial Officer & Executive Director
Vijay Laxman Kelkar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LUPIN LIMITED0.00%10 191
JOHNSON & JOHNSON8.98%304 536
PFIZER INC.-2.14%191 699
ROCHE HOLDING LTD.-19.65%189 885
NOVARTIS AG-20.79%180 598
MERCK & CO., INC.15.73%166 118
More Results